Lorazepam

Pain management compliance monitoring, forensic toxicology investigations, drug-facilitated crime assessments where its amnesic properties are exploited, and clinical toxicology screening all require accurate lorazepam detection. Unique analytical challenges arise because lorazepam is metabolized almost exclusively to lorazepam glucuronide, which has negligible cross-reactivity with standard benzodiazepine immunoassays, resulting in false-negative rates as high as 50% and necessitating LC-MS/MS confirmatory methods. UTAK’s benzodiazepines panels, DAU panels, and SAMHSA confirmation controls contain lorazepam in urine, whole blood, and oral fluid matrices at multiple concentration levels, supporting both immunoassay screening and LC-MS/MS confirmatory methods. Stock and custom QC solutions can incorporate related benzodiazepines such as alprazolam, clonazepam, diazepam, oxazepam, temazepam, midazolam, nordiazepam, triazolam, and other commonly monitored sedative-hypnotics to address your laboratory’s comprehensive benzodiazepine panel and pain management testing requirements.